All In Biotech

Free tool

FAERS Monitor: Angeliq

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021355 or its brand name (Angeliq, Drospirenone, Estradiol). Reports on generic versions are filed under their own applications.

Reports

540

Serious

312

58% of reports

Hospitalization

102

Death reported

11

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • headache31
  • vaginal haemorrhage30
  • hot flush26
  • fatigue25
  • drug ineffective24
  • nausea24
  • dizziness23
  • metrorrhagia23
  • alopecia22
  • anxiety22
  • malaise22
  • abdominal pain21
  • off label use21
  • pain20
  • pain in extremity17

Reports by year received

View as table
YearReports
20052
20068
20077
200889
200954
201016
201147
201212
201329
201430
201511
201619
201717
201821
201921
202029
202116
202217
202315
202416
202560
20264

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,619 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
metrorrhagiaSignal2352.635.31,113
vaginal haemorrhageSignal3026.919.0725
hot flushSignal2613.49.2288
alopeciaSignal224.42.954
abdominal painSignal213.52.336
anxietySignal223.02.028
pain in extremitySignal172.21.411
malaise222.01.310
headache311.91.413
dizziness231.81.28
pain201.30.81
fatigue251.30.91
nausea241.20.81
off label use210.90.60
drug ineffective240.70.53

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.